
Opinion|Videos|July 30, 2024
Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
Medical experts review the Ideate-Lung02 phase 3 clinical trial, exploring the potential for ifinatamab to elicit durable responses in patients with advanced small cell lung cancer (SCLC), and discussing the implications of these findings for the future treatment landscape of SCLC.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- B. Ideate-Lung02: Phase 3 Clinical Trial of Ifinatamab Deruxtecan vs TPC in Relapsed ES-SCL [TPS8126]
- Please share your perceptions of the potential for durable response to ifinatamab, a B7-H3-directed ADC in patients with previously treated, relapsed SCLC.
- How encouraging is an ORR of 52.4%, a 5.9-month median DoR, and a 12.2-month
- OS after a median 2 prior lines of therapy as reported in the Phase I/II trial?
- Currently, can you assay B7-H3 to determine individual expression levels?
- How does a treatment schedule of 12 mg/kg IV Q3W compare with that of:
- amrubicin [(Calsed) aminoanthracycline]: 45mg/m2 IV Infusion QD x 3 days Q3W [Japan]
- topotecan [(Hycamtin) topoisomerase inhibitor]: 1.5 mg/m2 IV infusion QD, Days 1-5 Q3W
- lurbinectedin [(Zepzelca) alkylating agent]: 3.2 mg/m2IV infusion Q3W
- What is the potential for immunogenicity with this ADC, and which treatment-related adverse events would most concern you?
Advertisement
Related to this article

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Giredestrant Plus Everolimus for ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer
2
Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC
3
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
4
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
5

